Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in heart failure with preserved or mildly reduced ejection fraction (NYHA II–IV, LVEF ≥40%)
jRCT2080225274Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Finerenone with Placebo (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Started Jul 2020; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on jRCT2080225274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225274.